Your browser doesn't support javascript.
loading
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Rodler, Eve T; Kurland, Brenda F; Griffin, Melissa; Gralow, Julie R; Porter, Peggy; Yeh, Rosa F; Gadi, Vijayakrishna K; Guenthoer, Jamie; Beumer, Jan H; Korde, Larissa; Strychor, Sandra; Kiesel, Brian F; Linden, Hannah M; Thompson, John A; Swisher, Elizabeth; Chai, Xiaoyu; Shepherd, Stacie; Giranda, Vincent; Specht, Jennifer M.
Afiliação
  • Rodler ET; University of California, Davis, California. erodler@ucdavis.edu.
  • Kurland BF; University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Griffin M; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Gralow JR; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Porter P; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Yeh RF; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Gadi VK; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Guenthoer J; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Beumer JH; University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Korde L; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Strychor S; University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Kiesel BF; University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Linden HM; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Thompson JA; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Swisher E; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Chai X; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Shepherd S; AbbVie Laboratories, North Chicago, Illinois.
  • Giranda V; AbbVie Laboratories, North Chicago, Illinois.
  • Specht JM; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington.
Clin Cancer Res ; 22(12): 2855-64, 2016 06 15.
Article em En | MEDLINE | ID: mdl-26801247
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vimblastina / Benzimidazóis / Protocolos de Quimioterapia Combinada Antineoplásica / Cisplatino / Proteína BRCA2 / Ubiquitina-Proteína Ligases / Neoplasias de Mama Triplo Negativas / Inibidores de Poli(ADP-Ribose) Polimerases / Antineoplásicos Fitogênicos Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vimblastina / Benzimidazóis / Protocolos de Quimioterapia Combinada Antineoplásica / Cisplatino / Proteína BRCA2 / Ubiquitina-Proteína Ligases / Neoplasias de Mama Triplo Negativas / Inibidores de Poli(ADP-Ribose) Polimerases / Antineoplásicos Fitogênicos Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article